Novartis | NVS - Loan Capital


Novartis reported $37.45B in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
AbbVie USD 58.94B 4.03B Dec/2025
Amgen USD 51.89B 1.88B Mar/2026
AstraZeneca USD 25.96B 177M Mar/2026
Bausch Health Companies USD 19.9B 720M Mar/2026
Biogen USD 6.29B 1.7M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Canopy Growth CAD 217.12M 7.87M Mar/2026
Drreddys Laboratories INR 12.2B 12.07B Mar/2026
Eli Lilly USD 39.37B 1.5B Mar/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Glaxosmithkline GBP 18.53B 1.29B Mar/2026
J&J USD 37.53B 1.91B Mar/2026
Merck USD 46.67B 77M Mar/2026
Novartis USD 37.45B 7.86B Mar/2026
Novartis USD 37.45B 7.86B Mar/2026
Pacira USD 367.66M 4.53M Mar/2026
Perrigo USD 3.62B 17.5M Mar/2026
Pfizer USD 60.57B 1.08B Mar/2026
Phibro Animal Health USD 597.68M 5.92M Mar/2026
Prestige Brands USD 1.01B 40.28M Mar/2026
Roche Holding CHF 27.43B 966M Dec/2025
Sanofi EUR 13.84B 1.88B Mar/2026
Sanofi EUR 12.3B 3.42B Mar/2026
Supernus Pharmaceuticals USD 400.38M 21.13M Mar/2022
Zoetis USD 9.04B 3M Mar/2026